Industry News

AAD Welcomes New Board Members

George J. Hruza, MD, President-Elect of the AAD

The American Academy of Dermatology (AAD) has elected new officers and board members, who took office following the academy’s annual meeting in March.

They include:

President-Elect: George J. Hruza, MD, MBA, FAAD. Dr. Hruza is as an adjunct professor of dermatology at St. Louis University. He is currently an assistant editor of the Journal of the American Academy of Dermatology and vice chair of SkinPAC, which works to raise the visibility of dermatology as a leader among physician specialties and within the health policy community.

Chaudhuri Appointed to Thesan Pharmaceuticals Board of Directors

Thesan Pharmaceuticals, a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions, has announced the appointment of Bhaskar Chaudhuri, PhD, to its Board of Directors. With more than 25 years of experience in pharmaceuticals—including management, and research and development—Dr. Chaudhuri most recently served as president of Valeant Pharmaceuticals before becoming an operating partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri also served as president and CEO of Dow Pharmaceuticals.

Educational Campaign on the Future of Cosmetic Procedures Launching This Spring

The International Society of Aesthetic Plastic Surgeons, the American Society for Dermatologic Surgery and aesthetic device manuafacturer Eclipse Aesthetics have teamed up with Mediaplanet Publishing to release an educational cross-media campaign titled “The Future of Cosmetic Procedures.” The campaign will launch this spring as a national online digital campaign and regionally in print as an eight to 12 page section distributed within the LA Times.

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios Announces Development Of Next-Generation Injectable Neurotoxin

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has announced development of a next-generation injectable botulinum toxin product, AI-09. Unlike currently commercialized botulinum toxin products that require reconstitution prior to injection, AI-09 will be packaged as a ready-to-use injectable liquid and is a complementary product to the company's topical botulinum prescription Phase IIb product ANT-1207, which is being developed for wrinkles, hyperhidrosis (excessive sweating) and acne.

Deepak Chadha Named VP of Regulatory Affairs at Suneva

Deepak Chadha

Suneva Medical has appointed Deepak Chadha to Vice President, Regulatory Affairs. With nearly two decades of regulatory experience, Chadha will be responsible for leading the development and implementation of Suneva Medical's regulatory strategies. Chadha comes to Suneva Medical after holding regulatory affairs positions at companies that include KYTHERA Biopharmaceuticals and Allergan Medical.

Valeant Donates $250,000 to the National Coalition Against Domestic Violence

Valeant Pharmaceuticals North America has donated $250,000 to the National Coalition Against Domestic Violence (NCADV). The donation is a reflection of Valeant's ongoing support and commitment to the well-being of women, and is the first of four checks the company will present to NCADV in a one year period for a combined donation goal of $1 million.